公开(公告)号：US20150104388A1

公开(公告)日：2015-04-16

申请号：US14578818

申请日：2014-12-22

申请人： THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

发明人： David H. COY ,  Jerome L. MADERDRUT ,  Min LI

IPC分类号： C07K14/575 ,  A61K47/48 ,  A61L31/08 ,  A61K45/06 ,  A61K51/08 ,  A61K38/22 ,  A61L31/16

CPC分类号： C07K14/57563 ,  A61K33/24 ,  A61K38/00 ,  A61K38/2278 ,  A61K45/06 ,  A61K47/64 ,  A61K51/088 ,  A61L31/08 ,  A61L31/16 ,  A61L2300/252 ,  A61L2300/40 ,  A61L2420/00 ,  C07K2319/50 ,  A61K2300/00

摘要： This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.

摘要翻译： 本发明涉及垂体腺苷酸环化酶活化多肽（PACAP）的新型类似物，其是PACAP /血管活性肠肽（VIP）受体的激动剂：PAC1，VPAC1和VPAC2受体。 这些PACAP类似物可以用作广泛的医学疾病的预防/治疗剂，包括（但不限于）癌症和自身免疫性疾病。 这些PACAP类似物可以耦合到合适的放射性核素，并用于弥散性癌症和转移性肿瘤的定位，诊断和治疗，或与小分子治疗剂偶联，并用作靶向药物递送的载体。 本发明还提供单独一种或与一种或多种其它预防/治疗剂组合的本发明的一种或多种PACAP样化合物的药物组合物。

公开(公告)号：US20160122406A1

公开(公告)日：2016-05-05

申请号：US14896178

申请日：2014-06-09

申请人： THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

发明人： David H. COY ,  Jerome L. MADERDRUT

IPC分类号： C07K14/47 ,  A61K51/08 ,  A61K49/00

CPC分类号： C07K14/4705 ,  A61K38/13 ,  A61K38/14 ,  A61K38/1816 ,  A61K45/06 ,  A61K47/64 ,  A61K49/0004 ,  A61K51/08 ,  C07K14/57563 ,  A61K2300/00

摘要： This invention relates to analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders. These PACAP analogs coupled to suitable radionuclides can be used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, and coupled to small molecule therapeutics can be used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP analogs of the invention either alone or in combination with one or more other prophylactic/therapeutic agent.

摘要翻译： 本发明涉及垂体腺苷酸环化酶活化多肽（PACAP）的类似物，其是PACAP /血管活性肠肽（VIP）受体的激动剂：PAC1，VPAC1和VPAC2受体。 这些PACAP类似物可用作广泛的医学疾病的预防/治疗剂。 耦合到合适的放射性核素的这些PACAP类似物可用于弥散性癌症和转移性肿瘤的定位，诊断和治疗，并且与小分子治疗剂相结合可用作靶向药物递送的载体。 本发明还提供单独的或与一种或多种其它预防/治疗剂组合的本发明的一种或多种PACAP类似物的药物组合物。